PULSE BIOSCIENCES INC (PLSE) Stock Price, Quote, News and Overview
NASDAQ:PLSE - Nasdaq - US74587B1017 - Common Stock - Currency: USD
PLSE Quote, Performance and Key Statistics
16.79
+1.69 (+11.19%)
The current stock price of PLSE is 16.79 USD. In the past month the price increased by 6.81%. In the past year, price decreased by -11.68%.
PLSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.41 | 225.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 59.92 | 172.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 36.22 | 151.64B | ||
| SYK | STRYKER CORP | 29.49 | 144.82B | ||
| MDT | MEDTRONIC PLC | 16.89 | 119.04B | ||
| BDX | BECTON DICKINSON AND CO | 13.73 | 56.16B | ||
| IDXX | IDEXX LABORATORIES INC | 55.28 | 53.39B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30.23 | 45.57B | ||
| RMD | RESMED INC | 30.19 | 42.27B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.17 | 34.49B | ||
| DXCM | DEXCOM INC | 47.04 | 31.35B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.34 | 26.28B |
Related stock screener links
About PLSE
Company Profile
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Company Info
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 75
Phone: 15109064600
PULSE BIOSCIENCES INC / PLSE FAQ
What is the stock price of PULSE BIOSCIENCES INC today?
The current stock price of PLSE is 16.79 USD. The price increased by 11.19% in the last trading session.
What is the ticker symbol for PULSE BIOSCIENCES INC stock?
The exchange symbol of PULSE BIOSCIENCES INC is PLSE and it is listed on the Nasdaq exchange.
On which exchange is PLSE stock listed?
PLSE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PULSE BIOSCIENCES INC stock?
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 33.65% is expected in the next year compared to the current price of 16.79. Check the PULSE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PULSE BIOSCIENCES INC worth?
PULSE BIOSCIENCES INC (PLSE) has a market capitalization of 1.13B USD. This makes PLSE a Small Cap stock.
How many employees does PULSE BIOSCIENCES INC have?
PULSE BIOSCIENCES INC (PLSE) currently has 75 employees.
What are the support and resistance levels for PULSE BIOSCIENCES INC (PLSE) stock?
PULSE BIOSCIENCES INC (PLSE) has a support level at 14.71 and a resistance level at 21.48. Check the full technical report for a detailed analysis of PLSE support and resistance levels.
Should I buy PULSE BIOSCIENCES INC (PLSE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PLSE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PLSE, evaluating the profitability, health, valuation and growth aspects
- PULSE BIOSCIENCES INC (PLSE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PULSE BIOSCIENCES INC (PLSE) Sales and EPS estimates to see what analysts future expectations are.
- PULSE BIOSCIENCES INC (PLSE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PULSE BIOSCIENCES INC (PLSE) Insider and Institutional Ownership to learn about the owners and their transactions.
- PULSE BIOSCIENCES INC (PLSE) Stock Chart to make your own analysis
- PULSE BIOSCIENCES INC (PLSE) Latest news and press-releases to stay up to date.
Does PULSE BIOSCIENCES INC (PLSE) stock pay dividends?
PLSE does not pay a dividend.
When does PULSE BIOSCIENCES INC (PLSE) report earnings?
PULSE BIOSCIENCES INC (PLSE) will report earnings on 2025-10-28.
What is the Price/Earnings (PE) ratio of PULSE BIOSCIENCES INC (PLSE)?
PULSE BIOSCIENCES INC (PLSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
What is the Short Interest ratio of PULSE BIOSCIENCES INC (PLSE) stock?
The outstanding short interest for PULSE BIOSCIENCES INC (PLSE) is 13.92% of its float. Check the ownership tab for more information on the PLSE short interest.
PLSE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PLSE. When comparing the yearly performance of all stocks, PLSE is a bad performer in the overall market: 80.24% of all stocks are doing better.
PLSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLSE. While PLSE has a great health rating, there are worries on its profitability.
PLSE Financial Highlights
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 55.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -45.17% | ||
| ROE | -50.86% | ||
| Debt/Equity | 0 |
PLSE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to PLSE. The Buy consensus is the average rating of analysts ratings from 7 analysts.